JHMD - ETF AI Analysis

Top Page

John Hancock Multifactor Developed International ETF (JHMD)

Rating:66Neutral

Price Target:―

The John Hancock Multifactor Developed International ETF (JHMD) receives a solid overall rating, driven by strong contributions from holdings like Novartis AG and Toyota. Novartis benefits from robust profitability, growth in key products, and positive earnings sentiment, while Toyota's strong financial health and balanced valuation metrics further enhance the fund's quality. However, weaker performers like BASF SE, which faces challenges in profitability and valuation concerns, slightly weigh on the ETF's overall score. Investors should also note the fund's exposure to diverse sectors and regions, which helps mitigate concentrated risk.

Positive Factors

Strong Geographic Diversification

The ETF invests across multiple countries, including Japan, the UK, and Germany, reducing reliance on any single economy.

Healthy Top Holdings Performance

Several top holdings, such as ASML Holding NV and Banco Bilbao Vizcaya Argentaria, have shown strong year-to-date gains, supporting the fund's overall performance.

Reasonable Expense Ratio

The ETF's expense ratio of 0.39% is competitive, making it a cost-effective option for international exposure.

Negative Factors

Sector Over-Concentration

The fund has significant exposure to the Financial and Industrials sectors, which may increase vulnerability to sector-specific downturns.

Mixed Holdings Performance

Some top holdings, such as BASF SE and Deutsche Telekom, have delivered weaker year-to-date returns, potentially dragging on overall performance.

Limited U.S. Exposure

With only 4.4% allocated to U.S. companies, the ETF may miss out on opportunities in the world's largest economy.

JHMD vs. SPDR S&P 500 ETF (SPY)

AUM996.72M

RegionDeveloped Markets

Expense Ratio0.39%

Beta0.66

IssuerJohn Hancock

Inception DateDec 15, 2016

Dividend Yield2.74%

Asset ClassEquity

Index TrackedJohn Hancock Dimensional Developed International Index

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume368,255

30 Day Avg. Volume109,621

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

45.39

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering575

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

JHMD Summary

The John Hancock Multifactor Developed International ETF (JHMD) is an investment fund that focuses on companies in developed international markets, such as Japan, the UK, and Germany. It includes a mix of large, mid, and small-sized companies across various industries like financials, healthcare, and technology. Some well-known companies in this ETF are Novartis and Nestlé. Investors might consider JHMD for diversification, as it provides exposure to stable economies outside the U.S. However, new investors should be aware that the ETF’s performance can be affected by global economic conditions, which may cause its value to fluctuate.

How much will it cost me?The John Hancock Multifactor Developed International ETF (JHMD) has an expense ratio of 0.39%, which means you’ll pay $3.90 per year for every $1,000 invested. This cost is slightly higher than average for passively managed ETFs because it uses a multifactor strategy to optimize risk and reward across developed international markets.

What would affect this ETF?Positive drivers for JHMD include potential economic growth in developed international markets outside North America, which could boost the performance of its top holdings like Vinci SA and Novartis AG. However, negative factors such as rising interest rates or economic slowdowns in Europe could impact sectors like Financials and Industrials, which make up a significant portion of the ETF's exposure.

JHMD Top 10 Holdings

The John Hancock Multifactor Developed International ETF (JHMD) leans heavily into financials and industrials, which together make up a significant portion of its portfolio. Banco Bilbao Vizcaya Argentaria (BBVA) and HSBC Holdings are rising stars, delivering strong gains thanks to robust revenue growth and favorable technical trends. Meanwhile, ASML Holding NV is another standout, benefiting from solid financials and momentum in the tech sector. On the flip side, Shell and AstraZeneca are lagging slightly, with Shell facing short-term weakness and AstraZeneca grappling with valuation concerns. Overall, the fund’s developed international focus provides a balanced mix of sectors and geographic exposure, with Europe playing a central role in its performance story.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
0NQM	Vinci SA	1.66%	$16.58M	€66.81B	24.35%	76 Outperform
NOVN	Novartis AG	1.50%	$15.04M	CHF206.54B	25.14%	80 Outperform
ASML	ASML Holding NV	1.30%	$13.04M	€344.40B	32.49%	76 Outperform
SHEL	Shell (UK)	1.21%	$12.11M	£154.14B	12.88%	73 Outperform
BBVA	Banco Bilbao Vizcaya Argentaria	1.04%	$10.46M	€113.69B	104.53%	76 Outperform
0005	HSBC Holdings	0.90%	$9.04M	HK$2.09T	53.39%	80 Outperform
BAS	BASF SE	0.88%	$8.79M	€39.06B	3.31%	61 Neutral
ROG	Roche Holding AG	0.81%	$8.09M	CHF260.13B	51.31%	73 Outperform
7203	Toyota Motor	0.81%	$8.07M	¥44.63T	23.54%	80 Outperform
AZN	AstraZeneca	0.77%	$7.72M	£211.95B	33.31%	80 Outperform

JHMD Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

40.63

Positive

100DMA

40.12

Positive

200DMA

38.20

Positive

Market Momentum

MACD

0.37

Negative

RSI

63.47

Neutral

STOCH

85.71

Negative

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For JHMD, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 41.13, equal to the 50-day MA of 40.63, and equal to the 200-day MA of 38.20, indicating a bullish trend. The MACD of 0.37 indicates Negative momentum. The RSI at 63.47 is Neutral, neither overbought nor oversold. The STOCH value of 85.71 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JHMD.

JHMD Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
JHMD	―	―	$996.72M	0.39%	―
QEFA	―	―	$962.55M	0.30%	―
GSID	―	―	$957.57M	0.20%	―
IQDG	―	―	$752.12M	0.42%	―
DMXF	―	―	$641.97M	0.12%	―
DWM	―	―	$630.15M	0.48%	―

Performance Comparison

JHMD

John Hancock Multifactor Developed International ETF

41.90

10.54

33.61%

QEFA

SPDR MSCI EAFE StrategicFactors ETF

―

GSID

Goldman Sachs MarketBeta International Equity ETF

―

IQDG

WisdomTree International Quality Dividend Growth Fund

―

DMXF

iShares ESG Advanced MSCI EAFE ETF

―

DWM

WisdomTree International Equity Fund

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents